Background. Many patients suffer from various manifestations even after four weeks of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) positivity and they are labelled as "Long COVID". Guidelines on pharmacological management of these patients are lacking till date.Methods. The present study is a retrospective analysis of "Long COVID" patients presenting to one of the units of Viswanathan Chest Hospital of our Institute between June 2020 and December 2020. All the records of these patients were analysed. Inclusion criteria was no pre-existing pulmonary disease and availability of follow-up visits. Systemic steroids had been given to patients with (a) resting hypoxia or (b) exertional desaturation along with radiological abnormalities, categorised as long COVID-interstitial lung disease (LC-ILD). The patients with breathlessness and wheeze or rhonchi on auscultation were categorised as long COVID-obstructive airway disease (LC-OAD). Inhaled corticosteroid and bronchodilators were given to them.Results. Out of the 3363 patients provided consultation in the OPD, 50 patients were categorised as of long-COVID. Only 10 patients fulfilled the inclusion criteria and were included in the present study. Two patients had hypoxia at rest and three patients with significant desaturation on six-minute walk test (6MWT). On chest radiography, six patients had bilateral lower zone reticulations/nonhomogeneous opacities. High resolution computed tomography confirmed ground-glass opacities (GGOs) in five of them. There were seven patients of LC-ILD, 2 of LC-OAD and 1 of "long COVID cough". LC-ILD patients responded to oral steroid therapy and showed clinical, radiological as well as functional improvement. In these patients both resting hypoxia and exertional desaturation disappeared. Also improvement in 6MWT distance was observed in these patients. Long COVID-OAD patients responded well to inhaled corticosteroids and bronchodilators with symptomatic and functional improvement.Conclusions. Patients of LC-ILD responded well to systemic steroids and LC-OAD to inhaled corticosteroids and bronchodilators. Despite the small number of patients, the present study provides a road-map for the management of "long COVID" pulmonary sequalae till large scale studies are being done.